

OVER
2 MIL
dogs treated
with Zenrelia*

ElancoTM

Reach for itch relief.
Reach for Zen. Reach for...

ZenreliaTM



Zenrelia, your first line JAK inhibitor **for dogs** with allergic and atopic dermatitis



Works fast

Visible improvement in itch from day one¹



More dogs back to normal²

Zenrelia (ilunocitinib) gets nearly 50% more itchy dogs back to normal compared to Apoquel® (oclacitinib)^{††}



Convenient dosing

Given once daily from day one



Zenrelia

does not interfere with the response to core booster vaccinations.^{‡3}

Find out more
about Zenrelia



* Elanco Data on File. Global Number of dogs treated with Zenrelia – as of March 2026. Up to 18 months of experience for dogs in USA, Canada, Japan and Brazil, UK, EU and Australia – a testament to Zenrelia's efficacy and safety.

[†] Results from comparison between Apoquel and Zenrelia: primary endpoint was non-inferiority demonstrated at day 28. At Day 112, 77% of dogs treated with Zenrelia achieved PVAS <2 compared to 53% of dogs treated with Apoquel. Secondary endpoint P values are not adjusted for multiple testing; therefore, caution should be exercised in interpretation. This was a subset of dogs treated for 112 days. A "normal" itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS <2).

^{††} When used according to label directions.

Read product leaflet for full instructions. For dogs from 12 months of age and 3 kg body weight.

Abbreviations: JAK, Janus Kinase; PVAS, Pruritus Visual Analog Scale.

References: 1. Forster S, et al. Vet Dermatol. 2025;36(2):165-176. 2. Rybnicek J, et al. Vet Dermatol. 2009;20(2):115-122. 3. Fent GM, et al. BMC Vet Res. 2025; 21:481.

Zenrelia, Elanco and the diagonal bar logo are trade marks of Elanco or its affiliates. Apoquel is a registered trade mark of Zoetis. © 2026 Elanco or its affiliates.

For further information contact Elanco Australasia Pty Ltd (ABN 64 076 745 198): productsupportau@elancoah.com. ELAN0775 07/26. PM-AU-26-0587.